Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Wall Street Zen to "Buy" Rating

Wall Street Zen upgraded shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday.

A number of other brokerages have also weighed in on PBH. Canaccord Genuity Group lifted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Oppenheimer lifted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Trading Up 0.6%

NYSE:PBH traded up $0.47 during trading hours on Friday, reaching $84.89. The company's stock had a trading volume of 381,921 shares, compared to its average volume of 297,202. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of 19.88, a PEG ratio of 2.69 and a beta of 0.44. The firm has a 50-day simple moving average of $83.48 and a 200-day simple moving average of $82.17. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. The business had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The company's revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.02 EPS. Research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Activity

In other news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in PBH. Barclays PLC grew its position in Prestige Consumer Healthcare by 346.3% during the third quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after buying an additional 71,730 shares during the period. Franklin Resources Inc. grew its position in Prestige Consumer Healthcare by 4.3% during the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company's stock valued at $1,513,000 after buying an additional 894 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Prestige Consumer Healthcare by 171.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 46,931 shares of the company's stock worth $3,665,000 after purchasing an additional 29,649 shares during the period. Diversify Wealth Management LLC increased its stake in shares of Prestige Consumer Healthcare by 35.3% in the fourth quarter. Diversify Wealth Management LLC now owns 10,399 shares of the company's stock worth $770,000 after purchasing an additional 2,713 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Prestige Consumer Healthcare by 18.8% in the fourth quarter. SG Americas Securities LLC now owns 5,996 shares of the company's stock worth $468,000 after purchasing an additional 947 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.